PDCD1 and neoplasm: More recently, the combination of lenvatinib with anti-programmed cell death protein-1 (PD-1) antibody pembrolizumab showed encouraging anti-tumor activity in patients with untreated/unresectable HCC with an ORR of 36%, a mPFS of 8.6 months, and a mOS of 22.0 months [112].